{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T04:15:24Z","timestamp":1793852124008,"version":"4.6.1"},"reference-count":28,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,12,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Heavy menstrual bleeding (HMB) is a common complication of anticoagulation, affecting \u223c70% of menstruating women receiving oral anticoagulants. The risk of HMB is lower with apixaban and\/or dabigatran than with rivaroxaban. HMB can result in iron deficiency with or without anemia, increased need for medical interventions, decreased quality of life, and missed school\/work. Mainstays of treatment include hormone therapies such as the levonorgestrel intrauterine system, subdermal implant, and other progesterone-based therapies, which can result in decreased blood loss and, in some cases, amenorrhea. Combined hormone therapies can be used while patients continue receiving anticoagulation and are also highly effective for decreasing menstrual blood loss. Rarely, procedure-based interventions such as endometrial ablation may be required. Patients should be evaluated for iron deficiency and anemia and offered supportive therapies as needed. Abbreviating the course of anticoagulation or skipping doses can increase the risk of recurrent venous thromboembolism by as much as fivefold, but switching oral anticoagulants may be considered. Awareness of HMB and careful history taking at each visit are crucial to avoid a missed diagnosis.<\/jats:p>","DOI":"10.1182\/hematology.2020000138","type":"journal-article","created":{"date-parts":[[2020,12,5]],"date-time":"2020-12-05T03:34:50Z","timestamp":1607139290000},"page":"533-537","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":39,"title":["Management of heavy menstrual bleeding on anticoagulation"],"prefix":"10.1182","volume":"2020","author":[{"given":"Bethany","family":"Samuelson Bannow","sequence":"first","affiliation":[{"name":"Oregon Health & Science University, Portland, OR"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"1","key":"2020121621260260800_B1","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1097\/AOG.0b013e318262e320","article-title":"Practice bulletin no. 128: diagnosis of abnormal uterine bleeding in reproductive-aged women","volume":"120","author":"Committee on Practice Bulletins\u2014Gynecology","year":"2012","journal-title":"Obstet Gynecol"},{"issue":"4","key":"2020121621260260800_B2","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1159\/000320336","article-title":"Pictorial blood loss assessment chart in the evaluation of heavy menstrual bleeding: diagnostic accuracy compared to alkaline hematin","volume":"71","author":"Zakherah","year":"2011","journal-title":"Gynecol Obstet Invest"},{"issue":"5","key":"2020121621260260800_B3","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1016\/j.ajog.2003.11.015","article-title":"Menorrhagia I: measured blood loss, clinical features, and outcome in women with heavy periods: a survey with follow-up data","volume":"190","author":"Warner","year":"2004","journal-title":"Am J Obstet Gynecol"},{"issue":"5","key":"2020121621260260800_B4","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.3892\/etm.2016.3144","article-title":"Heavy menstrual bleeding and health-associated quality of life in women with von Willebrand\u2019s disease","volume":"11","author":"Govorov","year":"2016","journal-title":"Exp Ther Med"},{"issue":"4","key":"2020121621260260800_B5","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.thromres.2015.07.030","article-title":"Abnormal uterine bleeding in VTE patients treated with rivaroxaban compared to vitamin K antagonists","volume":"136","author":"De Crem","year":"2015","journal-title":"Thromb Res"},{"key":"2020121621260260800_B6","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.vph.2016.11.003","article-title":"Heavy menstrual bleeding in women treated with rivaroxaban and vitamin K antagonists and the risk of recurrent venous thromboembolism","volume":"87","author":"Bryk","year":"2016","journal-title":"Vascul Pharmacol"},{"issue":"4","key":"2020121621260260800_B7","doi-asserted-by":"crossref","first-page":"887","DOI":"10.12669\/pjms.35.4.907","article-title":"The effect of oral progesterone for the treatment of abnormal uterine bleeding in women taking warfarin following prosthetic valve replacement","volume":"35","author":"Nadeem","year":"2019","journal-title":"Pak J Med Sci"},{"key":"2020121621260260800_B8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.vph.2017.05.001","article-title":"Abnormal uterine bleeding in women receiving direct oral anticoagulants for the treatment of venous thromboembolism","volume":"93-95","author":"Godin","year":"2017","journal-title":"Vascul Pharmacol"},{"issue":"9","key":"2020121621260260800_B9","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1111\/jth.14226","article-title":"Less abnormal uterine bleeding with dabigatran than warfarin in women treated for acute venous thromboembolism","volume":"16","author":"Huisman","year":"2018","journal-title":"J Thromb Haemost"},{"issue":"7","key":"2020121621260260800_B10","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1111\/jth.12230","article-title":"Edoxaban for the long-term treatment of venous thromboembolism: rationale and design of the Hokusai-venous thromboembolism study \u2013 methodological implications for clinical trials","volume":"11","author":"Raskob","year":"2013","journal-title":"J Thromb Haemost"},{"issue":"12","key":"2020121621260260800_B11","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1111\/1471-0528.15388","article-title":"Abnormal vaginal bleeding in women of reproductive age treated with edoxaban or warfarin for venous thromboembolism: a post hoc analysis of the Hokusai-VTE study","volume":"125","author":"Scheres","year":"2018","journal-title":"BJOG"},{"issue":"11","key":"2020121621260260800_B12","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1182\/blood-2015-08-665927","article-title":"Recurrent venous thromboembolism and abnormal uterine bleeding with anticoagulant and hormone therapy use","volume":"127","author":"Martinelli","year":"2016","journal-title":"Blood"},{"issue":"4","key":"2020121621260260800_B13","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1160\/TH16-11-0874","article-title":"Abnormal vaginal bleeding in women with venous thromboembolism treated with apixaban or warfarin","volume":"117","author":"Brekelmans","year":"2017","journal-title":"Thromb Haemost"},{"issue":"2","key":"2020121621260260800_B14","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/bjh.13583","article-title":"Heavy menstrual bleeding on rivaroxaban","volume":"173","author":"Ferreira","year":"2016","journal-title":"Br J Haematol"},{"issue":"5","key":"2020121621260260800_B15","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1111\/bjh.14003","article-title":"Heavy menstrual bleeding on rivaroxaban \u2013 comparison with apixaban","volume":"176","author":"Myers","year":"2017","journal-title":"Br J Haematol"},{"issue":"2","key":"2020121621260260800_B16","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0010-7824(01)00302-X","article-title":"Bleeding patterns and clinical performance of the levonorgestrel-releasing intrauterine system (Mirena) up to two years","volume":"65","author":"Hidalgo","year":"2002","journal-title":"Contraception"},{"issue":"1","key":"2020121621260260800_B17","first-page":"26","article-title":"Levonorgestrel intrauterine system (Mirena): an emerging tool for conservative treatment of abnormal uterine bleeding","volume":"6","author":"Dhamangaonkar","year":"2015","journal-title":"J Midlife Health"},{"issue":"5","key":"2020121621260260800_B18","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.contraception.2015.01.021","article-title":"Ovarian cysts: presence and persistence with use of a 13.5 mg levonorgestrel-releasing intrauterine system","volume":"91","author":"Nahum","year":"2015","journal-title":"Contraception"},{"issue":"5","key":"2020121621260260800_B19","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.contraception.2004.11.007","article-title":"Safety and efficacy of Implanon, a single-rod implantable contraceptive containing etonogestrel","volume":"71","author":"Funk","year":"2005","journal-title":"Contraception"},{"key":"2020121621260260800_B20"},{"issue":"6","key":"2020121621260260800_B21","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.contraception.2016.04.014","article-title":"Progestin-only contraception and thromboembolism: a systematic review","volume":"94","author":"Tepper","year":"2016","journal-title":"Contraception"},{"issue":"4","key":"2020121621260260800_B22","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1783\/147118902101196784","article-title":"Bleeding problems and progestogen-only contraception","volume":"28","author":"Porter","year":"2002","journal-title":"J Fam Plann Reprod Health Care"},{"key":"2020121621260260800_B23","first-page":"CD000329","article-title":"Endometrial resection and ablation versus hysterectomy for heavy menstrual bleeding","volume":"8","author":"Fergusson","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"issue":"7","key":"2020121621260260800_B24","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1111\/j.1471-0528.2004.00158.x","article-title":"Evaluation of the effect of uterine artery embolisation on menstrual blood loss and uterine volume","volume":"111","author":"Khaund","year":"2004","journal-title":"BJOG"},{"issue":"10084","key":"2020121621260260800_B25","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1016\/S0140-6736(17)30638-4","article-title":"Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial","volume":"389","author":"WOMAN Trial Collaborators","year":"2017","journal-title":"Lancet"},{"issue":"9734","key":"2020121621260260800_B26","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0140-6736(10)60835-5","article-title":"Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial","volume":"376","author":"CRASH-2 trial collaborators","year":"2010","journal-title":"Lancet"},{"key":"2020121621260260800_B27","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/1756-0500-6-184","article-title":"Tranexamic acid and the reduction of blood loss in total knee and hip arthroplasty: a meta-analysis","volume":"6","author":"Gandhi","year":"2013","journal-title":"BMC Res Notes"},{"issue":"10241","key":"2020121621260260800_B28","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1016\/S0140-6736(20)30848-5","article-title":"Effects of a high-dose 24-h infusion of tranexamic acid on death and thromboembolic events in patients with acute gastrointestinal bleeding (HALT-IT): an international randomised, double-blind, placebo-controlled trial","volume":"395","author":"HALT-IT Trial Collaborators","year":"2020","journal-title":"Lancet"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2020\/1\/533\/1794948\/hem2020000138c.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2020\/1\/533\/1794948\/hem2020000138c.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,18]],"date-time":"2020-12-18T18:14:49Z","timestamp":1608315289000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2020\/1\/533\/474310\/Management-of-heavy-menstrual-bleeding-on"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,4]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12,4]]}},"URL":"https:\/\/doi.org\/10.1182\/hematology.2020000138","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,4]]}}}